Heatwurx (NASDAQ:PCSA – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($1.19) earnings per share (EPS) for the quarter, Zacks reports.
Heatwurx Trading Down 2.8%
Shares of PCSA traded down $0.07 during mid-day trading on Friday, reaching $2.43. The company’s stock had a trading volume of 49,930 shares, compared to its average volume of 647,212. Heatwurx has a 52 week low of $1.67 and a 52 week high of $14.24. The stock has a market cap of $6.73 million, a PE ratio of -0.26 and a beta of 0.99. The company’s fifty day moving average price is $2.23 and its two-hundred day moving average price is $2.50.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Heatwurx in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $25.00.
Heatwurx Company Profile
Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.
Read More
- Five stocks we like better than Heatwurx
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Heatwurx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heatwurx and related companies with MarketBeat.com's FREE daily email newsletter.
